- Home
- ACRE vs GNFT Comparison
ACRE vs GNFT Comparison
Compare ACRE & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRE
- GNFT
- Stock Information
- Founded
- ACRE 2011
- GNFT 1999
- Country
- ACRE United States
- GNFT France
- Employees
- ACRE N/A
- GNFT N/A
- Industry
- ACRE Real Estate Investment Trusts
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACRE Real Estate
- GNFT Health Care
- Exchange
- ACRE Nasdaq
- GNFT Nasdaq
- Market Cap
- ACRE 254.1M
- GNFT 216.7M
- IPO Year
- ACRE 2012
- GNFT 2019
- Fundamental
- Price
- ACRE $4.91
- GNFT $4.24
- Analyst Decision
- ACRE Hold
- GNFT Strong Buy
- Analyst Count
- ACRE 5
- GNFT 2
- Target Price
- ACRE $5.08
- GNFT $10.00
- AVG Volume (30 Days)
- ACRE 432.9K
- GNFT 9.4K
- Earning Date
- ACRE 11-07-2025
- GNFT 09-22-2025
- Dividend Yield
- ACRE 12.17%
- GNFT N/A
- EPS Growth
- ACRE N/A
- GNFT N/A
- EPS
- ACRE N/A
- GNFT N/A
- Revenue
- ACRE $87,777,000.00
- GNFT $52,994,715.00
- Revenue This Year
- ACRE N/A
- GNFT $3.14
- Revenue Next Year
- ACRE N/A
- GNFT N/A
- P/E Ratio
- ACRE N/A
- GNFT N/A
- Revenue Growth
- ACRE 122.65
- GNFT N/A
- 52 Week Low
- ACRE $3.35
- GNFT $2.55
- 52 Week High
- ACRE $7.49
- GNFT $4.79
- Technical
- Relative Strength Index (RSI)
- ACRE 59.07
- GNFT 54.62
- Support Level
- ACRE $4.33
- GNFT $4.10
- Resistance Level
- ACRE $4.98
- GNFT $4.38
- Average True Range (ATR)
- ACRE 0.18
- GNFT 0.19
- MACD
- ACRE 0.05
- GNFT 0.02
- Stochastic Oscillator
- ACRE 78.95
- GNFT 82.31
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.